Clinical Trial Detail

NCT ID NCT03674567
Title Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors FLX Bio, Inc.
Indications

nasopharynx carcinoma

breast cancer

ovarian cancer

cervical cancer

triple-receptor negative breast cancer

stomach cancer

lung non-small cell carcinoma

esophageal carcinoma

lymphoma

head and neck squamous cell carcinoma

transitional cell carcinoma

colorectal adenocarcinoma

Therapies

FLX475 + Pembrolizumab

FLX475

Age Groups: adult senior

No variant requirements are available.